Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

23 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-09-30

Study Completion Date

2015-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomized phase II trial is studying how well giving pazopanib with or without bicalutamide works in treating patients with prostate cancer that did not respond to hormone therapy. Pazopanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the amount of androgens made by the body. Giving pazopanib hydrochloride together with bicalutamide may be an effective treatment for prostate cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer

NCT00454571

Recurrent Prostate Cancer

COMPLETED PHASE2

Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer

NCT01200810

Adenocarcinoma of the Prostate Recurrent Prostate Cancer Stage IV Prostate Cancer

TERMINATED PHASE2

Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer

NCT00005028

Prostate Cancer

COMPLETED PHASE2

Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery

NCT03147196

Stage I Prostate Adenocarcinoma Stage II Prostate Adenocarcinoma

WITHDRAWN PHASE2

Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration

NCT00878436

Prostate Cancer Prostatic Neoplasms

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. To determine the therapeutic activity of GW786034 (pazopanib hydrochloride) with and without bicalutamide in the treatment of hormone-refractory prostate cancer using prostate specific antigen (PSA)-response rate.

SECONDARY OBJECTIVES:

I. To estimate objective tumor response in patients with measurable disease. II. To estimate the median time to progression. III. To investigate the safety and tolerability of GW786034 with and without bicalutamide.

IV. To estimate the median duration of PSA-response. V. To determine the steady state levels of GW786034 with and without bicalutamide.

VI. To investigate the correlation between prior exposure to bicalutamide and non-steroidal anti-androgens with response and survival outcomes.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive pazopanib hydrochloride orally (PO) once daily (QD) on days 1-28.

ARM II: Patients receive pazopanib hydrochloride PO QD on days 1-28. Patients also receive bicalutamide PO QD on days 8-28 of course 1 and on days 1-28 in all subsequent courses.

Courses in both arms repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 4 weeks for 12 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hormone-Resistant Prostate Cancer Recurrent Prostate Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bicalutamide

Given PO

Intervention Type DRUG

Laboratory Biomarker Analysis

Correlative studies

Intervention Type OTHER

Pazopanib Hydrochloride

Given PO

Intervention Type DRUG

Pharmacological Study

Correlative studies

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Casodex Cosudex ICI 176,334 ICI 176334 GW786034B Votrient

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically or cytologically confirmed prostate cancer
* Must have received prior hormonal therapy, including either medical (luteinizing hormone-releasing hormone \[LHRH\] agonist) or surgical (orchiectomy) castration

* Castrate level of testosterone (\< 50 ng/dL)
* Patients treated with LHRH agonists must continue or restart this therapy
* Must have radiological documentation of either measurable or non-measurable disease
* Must show documented progression of prostate cancer while on hormonal therapy as indicated by PSA increase

* Rising PSA is defined as ≤ 2 consecutive rises in PSA taken ≥ 1 week and ≤ 2 months apart
* PSA \>= 5 ng/mL
* No known brain metastases
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 OR Karnofsky PS 60-100%
* Life expectancy \> 3 months
* White blood cell (WBC) \>= 3,000/mm\^3
* Absolute neutrophil count (ANC) \>= 1,500/mm\^3
* Platelet count \>= 100,000/mm\^3
* International normalized ratio (INR) =\< 1.2
* Activated partial thromboplastin time (PTT) =\< 1.2 times upper limit of normal (ULN)
* Bilirubin normal
* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 1.5 times ULN
* Creatinine normal OR creatinine clearance \>= 60 mL/min
* Fertile patients must use effective contraception
* No history of allergic reactions attributed to compounds of similar chemical or biological composition to pazopanib hydrochloride or bicalutamide
* Proteinuria =\< 1+ on 2 consecutive dipsticks taken \>= 1 week apart
* QTc \< 480 msec
* No significant electrocardiogram (ECG) abnormalities
* No poorly controlled hypertension (systolic blood pressure \[BP\] \> 150 mm Hg or diastolic BP \> 90 mm Hg)
* No condition (e.g., gastrointestinal \[GI\] tract disease resulting in an inability to take oral medication or a requirement for intravenous (IV) alimentation; prior surgical procedures affecting absorption; or active peptic ulcer disease) that impairs the ability to swallow and retain pazopanib hydrochloride tablets
* No serious or nonhealing wound, ulcer, or bone fracture
* No abdominal fistula, gastrointestinal (GI) perforation, or intra-abdominal abscess within the past 28 days
* No cerebrovascular accident within the past 6 months
* No myocardial infarction, cardiac arrhythmia, admission for unstable angina, cardiac angioplasty, or stenting within the past 12 weeks
* No venous thrombosis within the past 12 weeks
* No New York Heart Association (NYHA) class III-IV heart failure

* Patients with a history of NYHA class II heart failure who are asymptomatic on treatment are eligible
* No concurrent uncontrolled illness, including, but not limited to, ongoing or active infection
* No psychiatric illness or social situation that would preclude study compliance
* Recovered from all prior therapy
* Prior neoadjuvant or adjuvant chemotherapy allowed
* More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) or radiotherapy
* At least 4 weeks since prior antiandrogens
* At least 4 weeks since prior surgery
* No prior bicalutamide therapy lasting \> 3 months in duration
* Concurrent steroids allowed if no change in steroid dosage within the past 4 weeks
* No other concurrent investigational agents
* No concurrent therapeutic warfarin

* Concurrent low molecular weight heparin or prophylactic low-dose warfarin allowed
* No concurrent combination antiretroviral therapy for human immunodeficiency virus (HIV)-positive patients

Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No